BioCentury
ARTICLE | Financial News

Synthorx raises $63M in series C

May 4, 2018 4:20 PM UTC

Synthorx Inc. (La Jolla, Calif.) raised $63 million on April 30 in a series C round led by new investor OrbiMed Advisors. Fellow new investors Medicxi and Osage University Partners also participated in the round, as did existing investors Avalon Ventures, RA Capital and Correlation Ventures.

Synthorx is using synthetic biology to develop a pipeline of Synthorin cytokines. Synthorins contain unnatural amino acid sequences and are engineered to have extended half-lives and increased receptor specificity. The company, which launched in 2014, has created a strain of E. coli that incorporates the nucleotides into cellular processes to produce synthetic proteins by design...

BCIQ Company Profiles

Synthorx Inc.